Welcome to our dedicated page for Cigna Group SEC filings (Ticker: CI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cigna Group SEC filings document financial results, governance actions and material events for a global health company operating through Cigna Healthcare, Evernorth Health Services and related subsidiaries. Form 8-K reports cover results of operations and financial condition, Regulation FD outlook disclosures, board and committee changes, leadership succession matters and shareholder meeting results.
Proxy materials describe director elections, executive compensation, shareholder voting items, board composition and governance practices. The filing record also includes exhibits for earnings releases and Inline XBRL cover data, tying formal disclosures to the company’s pharmacy benefit services, specialty and care services, health benefits operations, compliance oversight and public-company capital structure.
The Cigna Group’s Chairman and CEO David Cordani exercised employee stock options and sold shares in a pre-planned series of transactions. On May 12–13, 2026, he exercised options covering 212,543 shares of common stock at exercise prices of $149.135 and $197.35 per share, converting them into common shares.
Over the same period, he conducted open-market sales totaling 201,878 shares of common stock at weighted average prices generally between about $286 and $299 per share, according to price ranges in the filing. These sales were made under a Rule 10b5-1 trading plan adopted on February 6, 2026, meaning they were pre-arranged rather than opportunistic.
After these transactions, Cordani directly owned 57,766 shares of Cigna Group common stock. The filing also lists additional indirect holdings, including shares held through a 401(k) plan, a trust, and a GRAT, which are separate from his direct position.
The Cigna Group has reaffirmed its outlook for full year 2026, expecting consolidated adjusted income from operations on a per share basis of at least $30.35 per share. This confirmation will be communicated in upcoming meetings with investors and analysts.
The company explains that adjusted income from operations excludes net investment gains or losses, amortization of acquired intangible assets, certain joint venture investment results and special items that management does not view as part of normal, recurring operations. It emphasizes that this is a non-GAAP measure and not a substitute for shareholders’ net income, and notes that a reconciliation to GAAP cannot be provided on a forward-looking basis because future investment results and special items are inherently uncertain.
CI submitted a Form 144 notice reporting proposed sales of Common Stock. The filing lists planned dispositions tied to 03/01/2026 restricted stock vesting (12,764 shares) and to option-related transactions dated 02/28/2017 (103,595 shares) and 02/28/2018 (85,519 shares). The broker listed is Fidelity Brokerage Services LLC.
The Cigna Group reported stronger results for the quarter ended March 31, 2026, driven mainly by pharmacy operations. Total revenues rose to $68.5 billion from $65.5 billion, as pharmacy revenues increased to $54.0 billion while premiums declined after the prior-year Medicare Advantage divestiture.
Shareholders’ net income grew to $1.65 billion from $1.32 billion, with diluted EPS rising to $6.26 from $4.85. Adjusted income from operations increased to $2.06 billion (or $7.79 per diluted share) from $1.84 billion ($6.74 per share), reflecting higher contributions from both Evernorth Health Services and Cigna Healthcare.
The company continued its multi‑year Strategic Optimization Program, recording $380 million of pre‑tax charges in the quarter, mainly severance, bringing program‑to‑date costs to $1.13 billion pre‑tax. Operating cash flow was $1.13 billion, cash and cash equivalents were $7.0 billion, and long‑term debt declined to $29.4 billion. The Board declared a quarterly dividend of $1.56 per share.
The Cigna Group reported strong first quarter 2026 results with broad-based growth across its businesses and a higher full-year outlook. Total revenues were $68.5 billion for the quarter, up from $65.5 billion a year earlier, driven mainly by pharmacy-related operations. Shareholders’ net income rose to $1.65 billion, or $6.26 per share, compared with $1.32 billion, or $4.85 per share, in first quarter 2025.
Adjusted income from operations was $2.06 billion, or $7.79 per share, versus $1.84 billion, or $6.74 per share, a year ago. Evernorth Health Services generated $58.4 billion in adjusted revenues and $1.47 billion in pre-tax adjusted income, while Cigna Healthcare delivered $11.5 billion in adjusted revenues and $1.51 billion in pre-tax adjusted income with a 13.2% pre-tax margin. The company now expects full-year 2026 consolidated adjusted income from operations of at least $30.35 per share, modestly above its prior projection.
Cigna Group/The reports that Vanguard Capital Management beneficially owns 19,814,433 shares of Common Stock, representing 7.51% of the class as of 03/31/2026. The filing states Vanguard Capital Management has sole dispositive power over 19,814,433 shares and sole voting power for 2,692,364 shares. The report is signed on 04/29/2026.
The Cigna Group reported the results of its 2026 annual shareholder meeting, where 237,225,441 shares were represented out of 263,660,761 entitled to vote, a participation rate of 89.97%.
Shareholders elected all 12 director nominees and gave advisory approval to executive compensation with 201,746,941 votes for and 17,359,954 against, with 513,936 abstentions. They ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for 2026 with 216,061,458 votes for and 21,030,077 against. A shareholder proposal to allow action by written consent did not pass, receiving 104,982,574 votes for and 114,173,793 against.
Cigna Group director Eric J. Foss received a grant of 782 shares of common stock on April 22, 2026. The shares were acquired at no cost as a compensation-related award and are held directly. Following this grant, Foss directly owns 36,696 shares of Cigna common stock.
McClellan Mark B. reported acquisition or exercise transactions in this Form 4 filing.
Cigna Group director Mark B. McClellan received a grant of 782 shares of common stock. The award was recorded at a price of $0.0000 per share, reflecting stock-based compensation rather than a market purchase. Following this grant, he directly holds 6,891 Cigna common shares.
Hathi Neesha reported acquisition or exercise transactions in this Form 4 filing.
Cigna Group director Neesha Hathi received a grant of 782 shares of common stock as compensation. The shares were awarded at a stated price of $0.0000 per share, indicating a non-cash grant rather than an open-market purchase. Following this award, Hathi directly holds 4,151 Cigna Group shares.